期刊文献+

44例犬乳腺肿瘤的病理学分析及p53和HER-2的蛋白表达 被引量:1

下载PDF
导出
摘要 为了对犬乳腺肿瘤分类,分析表皮生长因子受体-2(HER-2)与p53的过表达在肿瘤类型上的差异及影响,对所收集的犬乳腺肿瘤标本,进行石蜡切片、H.E.染色,划分肿瘤的病理类型,应用免疫组织化学法检测犬乳腺肿瘤中HER-2基因与p53基因的表达情况。结果 44例犬乳腺肿瘤病理组织切片中,共观察到纤维腺瘤、叶状肿瘤、导管乳头状瘤、浸润性导管癌、浸润性小叶癌(腺泡型)、小叶癌、黏液癌、髓样癌伴随淋巴细胞浸润、混合样癌9种类型;42例犬乳腺肿瘤的免疫组化结果中,HER-2在良性肿瘤中无表达,在恶性肿瘤中的表达率为38.9%,p53在犬乳腺肿瘤中的表达可达78.6%,而在恶性肿瘤中的表达率100%。结论 HER-2与p53的过表达有肿瘤类型的差异性。
出处 《中国兽医杂志》 CAS 北大核心 2015年第6期82-83,I0005,共3页 Chinese Journal of Veterinary Medicine
基金 国家自然科学基金(31372492)
  • 相关文献

参考文献10

二级参考文献34

  • 1Nakagawa T, Uyama R, Ohashi E, et al. The expression of sialyl Lewis X in canine and feline mammary gland tumors. The Journal of Veterinary Medical Science / The Japanese So ciety of Veterinary Science [J]. 2002, 64 (10):949- 952.
  • 2Jia-Lin Lee, Ching-Jin Chang, Szu-Ying Wu, et al. Secreted frizzled-related protein 2 (SFRP2) is highly expressed in canine mammary gland tumors but not in normal mammary glands [J]. Breast Cancer Research and Treatment, 2004, 84: 139-149.
  • 3Satomi Haga, Masanari Nakayama, Kouko Tatsumi, et al. Overexpression of the p53 gene product in canine mammary tumors[J]. Oncology Reports, 2001, 8:1215-1219.
  • 4EI-A Helal T, Khalifa A, Kamel A S. Imrnunohistochemical expression of p53 and c-erbB2 protein in breast cancer in Egypt [J]. AnticancerRes, 2000, 20(3B):2145-2150.
  • 5Poelman S M, Heimann R, Fleming G F, et al. Invariant p53 immunostain-ing in primary and recurrent breast cancer[J]. Eur J Cancer, 2004, 40(1) :28-32.
  • 6Van de Vijver MJ. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2).Eur J Cancer, 2001, 37Suppl 1: 11-17.
  • 7Ross JS, Gray GS. Targeted therapy for cancer: the HER-2/neu and Herceptin story. Clin Leadersh Manag Rev, 2003, 17:333-340.
  • 8Vogel-C, Cobieigh MA, Tripathy D? et al. First-line, single-agent Herceptin ( R ) ( trastuzumab ) in metastatic breast cancer: a preliminary report. Eur J Cancer, 2001, 37 Suppl 1:25-29.
  • 9Hammock L, Lewis M, Phillips C, et al. Strong Her-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol, 2005,36 : 1043-1047.
  • 10Ross JS, Fletcher JA, Linette GP, et al. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.Oncologist, 2003, 8:307-325.

共引文献92

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部